TMEM175

Across TCGA pan-cancer cohorts, TMEM175 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM175 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM175 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM175 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where TMEM175 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	IV	0.262	0.908	.022	10	view →
LUAD	OS	Quartile	All	0.923	0.593	.007	7	view →
PDAC	DFS	Median	All	0.630	1.000	.036	4	view →
LSCC	OS	Quartile	III,IV	0.916	0.531	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM175–CCRCC (DFS)

Open the CCRCC breakdown →